Clinical Trial Update: Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating cyclophosphamide and docetaxel every three weeks as neoadjuvant therapy for locally advanced breast cancer has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• DOCETAXEL (DOCETAXEL)

Snippet

Sponsor: Tufts Medical Center | Conditions: Breast Cancer | Phase 2 | Status: WITHDRAWN